ScinoPharm Breaks Ground for Changshu Plant

TAINAN, Taiwan, Nov. 5 ScinoPharm-Changshu
TAINAN, Taiwan, Nov. 5 /PRNewswire-Asia/ -- ScinoPharm, a leading global supplier of active pharmaceutical ingredients (APIs), has commenced construction of a new plant on a 66670 square meter site. The facilities, located in Changshu, Jiangsu province in China, will include a R&D centre and production plants fully compliant with U.S. and international GMP standards.
The Changshu plant, slated to be fully operational by 2011, will be used for the production of GMP grade pharmaceutical intermediates initially, and later be equipped to handle API production. China's market for better quality APIs has grown considerably, and local formulation companies are encouraged to utilize APIs from companies having DMFs filed in advanced countries.
"The new site is part of ScinoPharm's long-term strategy to bolster its presence in China. Additional manufacturing and R&D facilities will complement our existing experience in selling quality APIs in regulated markets. The Changshu plant will serve as a launching pad for the rapidly expanding Chinese pharmaceutical market as well as a backup site to our customers," said Dr. Jo Shen, President and CEO of ScinoPharm.
"The Changshu facilities will help ScinoPharm's vertical integration with high quality intermediates, and will ensure final API products are of the highest quality and safety, yet at lower costs," added Dr. Hardy Chan, Executive Vice President and CSO of ScinoPharm.
ScinoPharm's investment in Changshu will also address the increasing number of multinational companies shifting their drug development research and clinical trials to China.
"They need supporting companies, like ScinoPharm, that are beyond medicinal chemistry companies and are knowledgeable about clinical API development, has experience handling FDA inquiries, and also inspections," commented Dr. Chan.
This expansion augments its current CMP manufacturing facility in Taiwan and allows the company to further support customer needs with a wide range of cost-competitive development and manufacturing solutions. ScinoPharm's current China operations include two research and development bases in Kunshan and Shanghai.
About ScinoPharm Taiwan
ScinoPharm Taiwan Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With cGMP production facilities, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. Combining cost-effective resources and productivity of Asia along with extensive regulatory know-how, ScinoPharm is uniquely positioned to serve global pharmaceutical R&D and manufacturing needs at any level and for any company in this sector. For more information please visit http://www.scinopharm.com .

    Media Contact:

     ScinoPharm Taiwan, Ltd.
     Jessie Wang
     Tel:   +886-6-505-2888
     Email: Jessie.wang@scinopharm.com.tw

SOURCE ScinoPharm Taiwan Ltd.